Compile Data Set for Download or QSAR
Report error Found 267 Enz. Inhib. hit(s) with all data for entry = 11958
TargetTyrosine-protein kinase JAK2 [Y1007F,Y1008F](Human)
Ajax Therapeutics, Inc.

US Patent
LigandPNGBDBM665067(US20240116892, Compound I-40)
Affinity DataKd: <10nMAssay Description:JAK2 (JH1 domain-catalytic, Y1007F, Y1008F) kinase was expressed as N-terminal fusion to the DNA binding domain of NFkB in transiently transfected HE...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/29/2024
Entry Details
US Patent

TargetTyrosine-protein kinase JAK2 [Y1007F,Y1008F](Human)
Ajax Therapeutics, Inc.

US Patent
LigandPNGBDBM665070(US20240116892, Compound I-42)
Affinity DataKd: <10nMAssay Description:JAK2 (JH1 domain-catalytic, Y1007F, Y1008F) kinase was expressed as N-terminal fusion to the DNA binding domain of NFkB in transiently transfected HE...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/29/2024
Entry Details
US Patent

TargetTyrosine-protein kinase JAK2 [Y1007F,Y1008F](Human)
Ajax Therapeutics, Inc.

US Patent
LigandPNGBDBM665080(US20240116892, Compound I-49-a)
Affinity DataKd: <10nMAssay Description:JAK2 (JH1 domain-catalytic, Y1007F, Y1008F) kinase was expressed as N-terminal fusion to the DNA binding domain of NFkB in transiently transfected HE...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/29/2024
Entry Details
US Patent

TargetTyrosine-protein kinase JAK2 [Y1007F,Y1008F](Human)
Ajax Therapeutics, Inc.

US Patent
LigandPNGBDBM665081(US20240116892, Compound I-49-b)
Affinity DataKd: <10nMAssay Description:JAK2 (JH1 domain-catalytic, Y1007F, Y1008F) kinase was expressed as N-terminal fusion to the DNA binding domain of NFkB in transiently transfected HE...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/29/2024
Entry Details
US Patent

TargetTyrosine-protein kinase JAK2 [Y1007F,Y1008F](Human)
Ajax Therapeutics, Inc.

US Patent
LigandPNGBDBM665075(US20240116892, Compound I-45-a)
Affinity DataKd: <10nMAssay Description:JAK2 (JH1 domain-catalytic, Y1007F, Y1008F) kinase was expressed as N-terminal fusion to the DNA binding domain of NFkB in transiently transfected HE...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/29/2024
Entry Details
US Patent

TargetTyrosine-protein kinase JAK2 [Y1007F,Y1008F](Human)
Ajax Therapeutics, Inc.

US Patent
LigandPNGBDBM665077(US20240116892, Compound I-46)
Affinity DataKd: <10nMAssay Description:JAK2 (JH1 domain-catalytic, Y1007F, Y1008F) kinase was expressed as N-terminal fusion to the DNA binding domain of NFkB in transiently transfected HE...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/29/2024
Entry Details
US Patent

TargetTyrosine-protein kinase JAK2 [Y1007F,Y1008F](Human)
Ajax Therapeutics, Inc.

US Patent
LigandPNGBDBM665056(US20240116892, Compound I-33-b)
Affinity DataKd: <10nMAssay Description:JAK2 (JH1 domain-catalytic, Y1007F, Y1008F) kinase was expressed as N-terminal fusion to the DNA binding domain of NFkB in transiently transfected HE...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/29/2024
Entry Details
US Patent

TargetTyrosine-protein kinase JAK2 [Y1007F,Y1008F](Human)
Ajax Therapeutics, Inc.

US Patent
LigandPNGBDBM665055(US20240116892, Compound I-33-a)
Affinity DataKd: <10nMAssay Description:JAK2 (JH1 domain-catalytic, Y1007F, Y1008F) kinase was expressed as N-terminal fusion to the DNA binding domain of NFkB in transiently transfected HE...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/29/2024
Entry Details
US Patent

TargetTyrosine-protein kinase JAK2 [Y1007F,Y1008F](Human)
Ajax Therapeutics, Inc.

US Patent
LigandPNGBDBM665058(US20240116892, Compound I-34-b)
Affinity DataKd: <10nMAssay Description:JAK2 (JH1 domain-catalytic, Y1007F, Y1008F) kinase was expressed as N-terminal fusion to the DNA binding domain of NFkB in transiently transfected HE...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/29/2024
Entry Details
US Patent

TargetTyrosine-protein kinase JAK2 [Y1007F,Y1008F](Human)
Ajax Therapeutics, Inc.

US Patent
LigandPNGBDBM665057(US20240116892, Compound I-34-a)
Affinity DataKd: <10nMAssay Description:JAK2 (JH1 domain-catalytic, Y1007F, Y1008F) kinase was expressed as N-terminal fusion to the DNA binding domain of NFkB in transiently transfected HE...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/29/2024
Entry Details
US Patent

TargetTyrosine-protein kinase JAK2 [Y1007F,Y1008F](Human)
Ajax Therapeutics, Inc.

US Patent
LigandPNGBDBM665052(US20240116892, Compound I-29-b)
Affinity DataKd: <10nMAssay Description:JAK2 (JH1 domain-catalytic, Y1007F, Y1008F) kinase was expressed as N-terminal fusion to the DNA binding domain of NFkB in transiently transfected HE...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/29/2024
Entry Details
US Patent

TargetTyrosine-protein kinase JAK2 [Y1007F,Y1008F](Human)
Ajax Therapeutics, Inc.

US Patent
LigandPNGBDBM665051(US20240116892, Compound I-29-a)
Affinity DataKd: <10nMAssay Description:JAK2 (JH1 domain-catalytic, Y1007F, Y1008F) kinase was expressed as N-terminal fusion to the DNA binding domain of NFkB in transiently transfected HE...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/29/2024
Entry Details
US Patent

TargetTyrosine-protein kinase JAK2 [Y1007F,Y1008F](Human)
Ajax Therapeutics, Inc.

US Patent
LigandPNGBDBM665054(US20240116892, Compound I-31)
Affinity DataKd: <10nMAssay Description:JAK2 (JH1 domain-catalytic, Y1007F, Y1008F) kinase was expressed as N-terminal fusion to the DNA binding domain of NFkB in transiently transfected HE...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/29/2024
Entry Details
US Patent

TargetTyrosine-protein kinase JAK2 [Y1007F,Y1008F](Human)
Ajax Therapeutics, Inc.

US Patent
LigandPNGBDBM665053(US20240116892, Compound I-30)
Affinity DataKd: <10nMAssay Description:JAK2 (JH1 domain-catalytic, Y1007F, Y1008F) kinase was expressed as N-terminal fusion to the DNA binding domain of NFkB in transiently transfected HE...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/29/2024
Entry Details
US Patent

TargetTyrosine-protein kinase JAK2 [Y1007F,Y1008F](Human)
Ajax Therapeutics, Inc.

US Patent
LigandPNGBDBM665064(US20240116892, Compound I-37-b)
Affinity DataKd: <10nMAssay Description:JAK2 (JH1 domain-catalytic, Y1007F, Y1008F) kinase was expressed as N-terminal fusion to the DNA binding domain of NFkB in transiently transfected HE...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/29/2024
Entry Details
US Patent

TargetTyrosine-protein kinase JAK2 [Y1007F,Y1008F](Human)
Ajax Therapeutics, Inc.

US Patent
LigandPNGBDBM665063(US20240116892, Compound I-37-a)
Affinity DataKd: <10nMAssay Description:JAK2 (JH1 domain-catalytic, Y1007F, Y1008F) kinase was expressed as N-terminal fusion to the DNA binding domain of NFkB in transiently transfected HE...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/29/2024
Entry Details
US Patent

TargetTyrosine-protein kinase JAK2 [Y1007F,Y1008F](Human)
Ajax Therapeutics, Inc.

US Patent
LigandPNGBDBM665066(US20240116892, Compound I-39)
Affinity DataKd: <10nMAssay Description:JAK2 (JH1 domain-catalytic, Y1007F, Y1008F) kinase was expressed as N-terminal fusion to the DNA binding domain of NFkB in transiently transfected HE...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/29/2024
Entry Details
US Patent

TargetTyrosine-protein kinase JAK2 [Y1007F,Y1008F](Human)
Ajax Therapeutics, Inc.

US Patent
LigandPNGBDBM665060(US20240116892, Compound I-35-b)
Affinity DataKd: <10nMAssay Description:JAK2 (JH1 domain-catalytic, Y1007F, Y1008F) kinase was expressed as N-terminal fusion to the DNA binding domain of NFkB in transiently transfected HE...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/29/2024
Entry Details
US Patent

TargetTyrosine-protein kinase JAK2 [Y1007F,Y1008F](Human)
Ajax Therapeutics, Inc.

US Patent
LigandPNGBDBM665059(US20240116892, Compound I-35-a)
Affinity DataKd: <10nMAssay Description:JAK2 (JH1 domain-catalytic, Y1007F, Y1008F) kinase was expressed as N-terminal fusion to the DNA binding domain of NFkB in transiently transfected HE...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/29/2024
Entry Details
US Patent

TargetTyrosine-protein kinase JAK2 [Y1007F,Y1008F](Human)
Ajax Therapeutics, Inc.

US Patent
LigandPNGBDBM665062(US20240116892, Compound I-36-b)
Affinity DataKd: <10nMAssay Description:JAK2 (JH1 domain-catalytic, Y1007F, Y1008F) kinase was expressed as N-terminal fusion to the DNA binding domain of NFkB in transiently transfected HE...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/29/2024
Entry Details
US Patent

TargetTyrosine-protein kinase JAK2 [Y1007F,Y1008F](Human)
Ajax Therapeutics, Inc.

US Patent
LigandPNGBDBM665061(US20240116892, Compound I-36-a)
Affinity DataKd: <10nMAssay Description:JAK2 (JH1 domain-catalytic, Y1007F, Y1008F) kinase was expressed as N-terminal fusion to the DNA binding domain of NFkB in transiently transfected HE...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/29/2024
Entry Details
US Patent

TargetTyrosine-protein kinase JAK2 [Y1007F,Y1008F](Human)
Ajax Therapeutics, Inc.

US Patent
LigandPNGBDBM665104(US20240116892, Compound I-64-b)
Affinity DataKd: <10nMAssay Description:JAK2 (JH1 domain-catalytic, Y1007F, Y1008F) kinase was expressed as N-terminal fusion to the DNA binding domain of NFkB in transiently transfected HE...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/29/2024
Entry Details
US Patent

TargetTyrosine-protein kinase JAK2 [Y1007F,Y1008F](Human)
Ajax Therapeutics, Inc.

US Patent
LigandPNGBDBM665103(US20240116892, Compound I-64-a)
Affinity DataKd: <10nMAssay Description:JAK2 (JH1 domain-catalytic, Y1007F, Y1008F) kinase was expressed as N-terminal fusion to the DNA binding domain of NFkB in transiently transfected HE...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/29/2024
Entry Details
US Patent

TargetTyrosine-protein kinase JAK2 [Y1007F,Y1008F](Human)
Ajax Therapeutics, Inc.

US Patent
LigandPNGBDBM665106(US20240116892, Compound I-66)
Affinity DataKd: <10nMAssay Description:JAK2 (JH1 domain-catalytic, Y1007F, Y1008F) kinase was expressed as N-terminal fusion to the DNA binding domain of NFkB in transiently transfected HE...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/29/2024
Entry Details
US Patent

TargetTyrosine-protein kinase JAK2 [Y1007F,Y1008F](Human)
Ajax Therapeutics, Inc.

US Patent
LigandPNGBDBM665105(US20240116892, Compound I-65)
Affinity DataKd: <10nMAssay Description:JAK2 (JH1 domain-catalytic, Y1007F, Y1008F) kinase was expressed as N-terminal fusion to the DNA binding domain of NFkB in transiently transfected HE...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/29/2024
Entry Details
US Patent

TargetTyrosine-protein kinase JAK2 [Y1007F,Y1008F](Human)
Ajax Therapeutics, Inc.

US Patent
LigandPNGBDBM665100(US20240116892, Compound I-62-b)
Affinity DataKd: <10nMAssay Description:JAK2 (JH1 domain-catalytic, Y1007F, Y1008F) kinase was expressed as N-terminal fusion to the DNA binding domain of NFkB in transiently transfected HE...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/29/2024
Entry Details
US Patent

TargetTyrosine-protein kinase JAK2 [Y1007F,Y1008F](Human)
Ajax Therapeutics, Inc.

US Patent
LigandPNGBDBM665099(US20240116892, Compound I-62-a)
Affinity DataKd: <10nMAssay Description:JAK2 (JH1 domain-catalytic, Y1007F, Y1008F) kinase was expressed as N-terminal fusion to the DNA binding domain of NFkB in transiently transfected HE...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/29/2024
Entry Details
US Patent

TargetTyrosine-protein kinase JAK2 [Y1007F,Y1008F](Human)
Ajax Therapeutics, Inc.

US Patent
LigandPNGBDBM665102(US20240116892, Compound I-63-b)
Affinity DataKd: <10nMAssay Description:JAK2 (JH1 domain-catalytic, Y1007F, Y1008F) kinase was expressed as N-terminal fusion to the DNA binding domain of NFkB in transiently transfected HE...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/29/2024
Entry Details
US Patent

TargetTyrosine-protein kinase JAK2 [Y1007F,Y1008F](Human)
Ajax Therapeutics, Inc.

US Patent
LigandPNGBDBM665101(US20240116892, Compound I-63-a)
Affinity DataKd: <10nMAssay Description:JAK2 (JH1 domain-catalytic, Y1007F, Y1008F) kinase was expressed as N-terminal fusion to the DNA binding domain of NFkB in transiently transfected HE...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/29/2024
Entry Details
US Patent

TargetTyrosine-protein kinase JAK2 [Y1007F,Y1008F](Human)
Ajax Therapeutics, Inc.

US Patent
LigandPNGBDBM665111(US20240116892, Compound I-70-b)
Affinity DataKd: <10nMAssay Description:JAK2 (JH1 domain-catalytic, Y1007F, Y1008F) kinase was expressed as N-terminal fusion to the DNA binding domain of NFkB in transiently transfected HE...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/29/2024
Entry Details
US Patent

TargetTyrosine-protein kinase JAK2 [Y1007F,Y1008F](Human)
Ajax Therapeutics, Inc.

US Patent
LigandPNGBDBM665114(US20240116892, Compound I-73)
Affinity DataKd: <10nMAssay Description:JAK2 (JH1 domain-catalytic, Y1007F, Y1008F) kinase was expressed as N-terminal fusion to the DNA binding domain of NFkB in transiently transfected HE...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/29/2024
Entry Details
US Patent

TargetTyrosine-protein kinase JAK2 [Y1007F,Y1008F](Human)
Ajax Therapeutics, Inc.

US Patent
LigandPNGBDBM665113(US20240116892, Compound I-72)
Affinity DataKd: <10nMAssay Description:JAK2 (JH1 domain-catalytic, Y1007F, Y1008F) kinase was expressed as N-terminal fusion to the DNA binding domain of NFkB in transiently transfected HE...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/29/2024
Entry Details
US Patent

TargetTyrosine-protein kinase JAK2 [Y1007F,Y1008F](Human)
Ajax Therapeutics, Inc.

US Patent
LigandPNGBDBM665108(US20240116892, Compound I-68)
Affinity DataKd: <10nMAssay Description:JAK2 (JH1 domain-catalytic, Y1007F, Y1008F) kinase was expressed as N-terminal fusion to the DNA binding domain of NFkB in transiently transfected HE...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/29/2024
Entry Details
US Patent

TargetTyrosine-protein kinase JAK2 [Y1007F,Y1008F](Human)
Ajax Therapeutics, Inc.

US Patent
LigandPNGBDBM665110(US20240116892, Compound I-70-a)
Affinity DataKd: <10nMAssay Description:JAK2 (JH1 domain-catalytic, Y1007F, Y1008F) kinase was expressed as N-terminal fusion to the DNA binding domain of NFkB in transiently transfected HE...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/29/2024
Entry Details
US Patent

TargetTyrosine-protein kinase JAK2 [Y1007F,Y1008F](Human)
Ajax Therapeutics, Inc.

US Patent
LigandPNGBDBM665109(US20240116892, Compound I-69)
Affinity DataKd: <10nMAssay Description:JAK2 (JH1 domain-catalytic, Y1007F, Y1008F) kinase was expressed as N-terminal fusion to the DNA binding domain of NFkB in transiently transfected HE...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/29/2024
Entry Details
US Patent

TargetTyrosine-protein kinase JAK2 [Y1007F,Y1008F](Human)
Ajax Therapeutics, Inc.

US Patent
LigandPNGBDBM665089(US20240116892, Compound I-55)
Affinity DataKd: <10nMAssay Description:JAK2 (JH1 domain-catalytic, Y1007F, Y1008F) kinase was expressed as N-terminal fusion to the DNA binding domain of NFkB in transiently transfected HE...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/29/2024
Entry Details
US Patent

TargetTyrosine-protein kinase JAK2 [Y1007F,Y1008F](Human)
Ajax Therapeutics, Inc.

US Patent
LigandPNGBDBM665097(US20240116892, Compound I-61-b | US20240116892, Co...)
Affinity DataKd: <10nMAssay Description:JAK2 (JH1 domain-catalytic, Y1007F, Y1008F) kinase was expressed as N-terminal fusion to the DNA binding domain of NFkB in transiently transfected HE...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/29/2024
Entry Details
US Patent

TargetTyrosine-protein kinase JAK2 [Y1007F,Y1008F](Human)
Ajax Therapeutics, Inc.

US Patent
LigandPNGBDBM665097(US20240116892, Compound I-61-b | US20240116892, Co...)
Affinity DataKd: <10nMAssay Description:JAK2 (JH1 domain-catalytic, Y1007F, Y1008F) kinase was expressed as N-terminal fusion to the DNA binding domain of NFkB in transiently transfected HE...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/29/2024
Entry Details
US Patent

TargetTyrosine-protein kinase JAK2 [Y1007F,Y1008F](Human)
Ajax Therapeutics, Inc.

US Patent
LigandPNGBDBM665092(US20240116892, Compound I-58-a)
Affinity DataKd: <10nMAssay Description:JAK2 (JH1 domain-catalytic, Y1007F, Y1008F) kinase was expressed as N-terminal fusion to the DNA binding domain of NFkB in transiently transfected HE...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/29/2024
Entry Details
US Patent

TargetTyrosine-protein kinase JAK2 [Y1007F,Y1008F](Human)
Ajax Therapeutics, Inc.

US Patent
LigandPNGBDBM665091(US20240116892, Compound I-57)
Affinity DataKd: <10nMAssay Description:JAK2 (JH1 domain-catalytic, Y1007F, Y1008F) kinase was expressed as N-terminal fusion to the DNA binding domain of NFkB in transiently transfected HE...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/29/2024
Entry Details
US Patent

TargetTyrosine-protein kinase JAK2 [Y1007F,Y1008F](Human)
Ajax Therapeutics, Inc.

US Patent
LigandPNGBDBM665094(US20240116892, Compound I-59)
Affinity DataKd: <10nMAssay Description:JAK2 (JH1 domain-catalytic, Y1007F, Y1008F) kinase was expressed as N-terminal fusion to the DNA binding domain of NFkB in transiently transfected HE...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/29/2024
Entry Details
US Patent

TargetTyrosine-protein kinase JAK2 [Y1007F,Y1008F](Human)
Ajax Therapeutics, Inc.

US Patent
LigandPNGBDBM665093(US20240116892, Compound I-58-b)
Affinity DataKd: <10nMAssay Description:JAK2 (JH1 domain-catalytic, Y1007F, Y1008F) kinase was expressed as N-terminal fusion to the DNA binding domain of NFkB in transiently transfected HE...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/29/2024
Entry Details
US Patent

TargetTyrosine-protein kinase JAK2 [Y1007F,Y1008F](Human)
Ajax Therapeutics, Inc.

US Patent
LigandPNGBDBM665135(US20240116892, Compound I-88-b)
Affinity DataKd: <10nMAssay Description:JAK2 (JH1 domain-catalytic, Y1007F, Y1008F) kinase was expressed as N-terminal fusion to the DNA binding domain of NFkB in transiently transfected HE...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/29/2024
Entry Details
US Patent

TargetTyrosine-protein kinase JAK2 [Y1007F,Y1008F](Human)
Ajax Therapeutics, Inc.

US Patent
LigandPNGBDBM665132(US20240116892, Compound I-87-a)
Affinity DataKd: <10nMAssay Description:JAK2 (JH1 domain-catalytic, Y1007F, Y1008F) kinase was expressed as N-terminal fusion to the DNA binding domain of NFkB in transiently transfected HE...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/29/2024
Entry Details
US Patent

TargetTyrosine-protein kinase JAK2 [Y1007F,Y1008F](Human)
Ajax Therapeutics, Inc.

US Patent
LigandPNGBDBM665131(US20240116892, Compound I-86)
Affinity DataKd: <10nMAssay Description:JAK2 (JH1 domain-catalytic, Y1007F, Y1008F) kinase was expressed as N-terminal fusion to the DNA binding domain of NFkB in transiently transfected HE...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/29/2024
Entry Details
US Patent

TargetTyrosine-protein kinase JAK2 [Y1007F,Y1008F](Human)
Ajax Therapeutics, Inc.

US Patent
LigandPNGBDBM665134(US20240116892, Compound I-88-a)
Affinity DataKd: <10nMAssay Description:JAK2 (JH1 domain-catalytic, Y1007F, Y1008F) kinase was expressed as N-terminal fusion to the DNA binding domain of NFkB in transiently transfected HE...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/29/2024
Entry Details
US Patent

TargetTyrosine-protein kinase JAK2 [Y1007F,Y1008F](Human)
Ajax Therapeutics, Inc.

US Patent
LigandPNGBDBM665133(US20240116892, Compound I-87-b)
Affinity DataKd: <10nMAssay Description:JAK2 (JH1 domain-catalytic, Y1007F, Y1008F) kinase was expressed as N-terminal fusion to the DNA binding domain of NFkB in transiently transfected HE...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/29/2024
Entry Details
US Patent

TargetTyrosine-protein kinase JAK2 [Y1007F,Y1008F](Human)
Ajax Therapeutics, Inc.

US Patent
LigandPNGBDBM665144(US20240116892, Compound I-95-a)
Affinity DataKd: <10nMAssay Description:JAK2 (JH1 domain-catalytic, Y1007F, Y1008F) kinase was expressed as N-terminal fusion to the DNA binding domain of NFkB in transiently transfected HE...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/29/2024
Entry Details
US Patent

TargetTyrosine-protein kinase JAK2 [Y1007F,Y1008F](Human)
Ajax Therapeutics, Inc.

US Patent
LigandPNGBDBM665143(US20240116892, Compound I-94)
Affinity DataKd: <10nMAssay Description:JAK2 (JH1 domain-catalytic, Y1007F, Y1008F) kinase was expressed as N-terminal fusion to the DNA binding domain of NFkB in transiently transfected HE...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/29/2024
Entry Details
US Patent

TargetTyrosine-protein kinase JAK2 [Y1007F,Y1008F](Human)
Ajax Therapeutics, Inc.

US Patent
LigandPNGBDBM665145(US20240116892, Compound I-95-b)
Affinity DataKd: <10nMAssay Description:JAK2 (JH1 domain-catalytic, Y1007F, Y1008F) kinase was expressed as N-terminal fusion to the DNA binding domain of NFkB in transiently transfected HE...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/29/2024
Entry Details
US Patent

Displayed 1 to 50 (of 267 total ) | Next | Last >>
Jump to: